Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | KDM1A | O60341 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | VNN1 | O95497 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13210601 | 0.88 | ALDH1A1 (0.68) | MEN1KMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL3402865 | 0.85 | MMP13 (0.67) | MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL27822779 | 0.83 | L3MBTL1 (0.81) | MEN1KMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL11761142 | 0.83 | NPC1 (0.82) | MEN1KMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL9416606 | 0.83 | NPC1 (0.82) | MEN1KMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL28443041 | 0.82 | L3MBTL1 (0.74) | MEN1KMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL5083105 | 0.82 | L3MBTL1 (0.74) | MEN1KMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL16562244 | 0.82 | RAB9A (0.74) | MEN1KMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL4067449 | 0.82 | L3MBTL1 (1.00) | L3MBTL1RAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL23985245 | 0.81 | NPC1 (0.61) | MEN1KMT2AL3MBTL1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2251333-A1 | Biphenyl derivatives as P-38 kinase inhibitors | Novartis AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| EP-1990338-B1 | Biphenylcyclopropylamides as p-38 Kinase inhibitors | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| EP-1990338-B1 | Biphenylcyclopropylamides as p-38 Kinase inhibitors | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100234404-A1 | P-38 Kinase Inhibitors | LANG HENGYUAN | 2010-09-16 | — | — | US | disclosed |
| US-20100234404-A1 | P-38 Kinase Inhibitors | LANG HENGYUAN | 2010-09-16 | — | — | US | disclosed |
| US-20100234404-A1 | P-38 Kinase Inhibitors | LANG HENGYUAN | 2010-09-16 | — | — | US | disclosed |
| US-7754726-B2 | Benzamide derivatives as p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754726-B2 | Benzamide derivatives as p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754726-B2 | Benzamide derivatives as p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7700622-B2 | p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-7700622-B2 | p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| EP-1990338-A2 | Biphenylcyclopropylamides as p-38 Kinase inhibitors | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1990338-A2 | Biphenylcyclopropylamides as p-38 Kinase inhibitors | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1687284-B1 | p-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-20070111999-A1 | P-38 kinase inhibitors | TRIAD THERAPEUTICS, INC (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111999-A1 | P-38 kinase inhibitors | TRIAD THERAPEUTICS, INC (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111999-A1 | P-38 kinase inhibitors | TRIAD THERAPEUTICS, INC (US) | 2007-05-17 | — | — | US | disclosed |
| EP-1687284-A2 | p-38 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005012241-A2 | p-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-10 | — | — | WO | disclosed |
| US-20050020590-A1 | P-38 kinase inhibitors | NOVARTIS AG (CH) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111999-A1 | P-38 kinase inhibitors | MAPK8, MAP3K8, MAPK1 | MEN1 4480/4885KMT2A 3583/4885L3MBTL1 1196/4885 |
| US-20050020590-A1 | P-38 kinase inhibitors | MAPK8, MAP3K8, MAPK1 | MEN1 4241/4885KMT2A 3537/4885L3MBTL1 1113/4885 |
| US-20100234404-A1 | P-38 Kinase Inhibitors | MAPK8, MAP3K8, MAPK1 | MEN1 4480/4885KMT2A 3583/4885L3MBTL1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.